md-medicaldata

Authors

 

Vladimir Djordjević¹, Aleksandra Buha², Zeljko Radojković¹, Nemanja Zarić¹, Slavenko Ostojić¹, Nebojša Lekić¹, Aleksandar Ninić¹, Milica Ćulafić³, Biljana Mihaljević ², Darko Antić ², Vojin Vuković², Mirko Kerkez^1
1 Clinic for Digestive Surgery, First Surgical Clinic, Clinical Center of Serbia, Belgrade, Serbia
² Department of Toxicology "Akademik Danilo Soldatović", University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia
³ Department of Pharmacokinetics and Clinical Pharmacy, University of Belgrade-Faculty of Pharmacy, Belgrade, Serbia
⁴ Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia

 

 Rad je primljen 21.11.2016 Prihvaćen 25.11.2016.

 

 

Correspondence to:
Aleksandra Buha
Katedra za toksikologiju "Akademik Danilo Soldatović"
Univerzitet u Beogradu-Farmaceutski fakultet
Vojvode Stepe 450
11000 Beograd
Kontakt telefon: 063/377-687
e-mail: aleksandra@pharmacy.bg.ac.rs

 

 

Abstract

 

Following solid organ transplantation, the patient's management includes the provision of immunosuppressive therapy to the recipient. All kidney transplant recipients require life-long immunosuppression. Regardless the improving survival following solid organ transplantation, post-transplant complications such as the development of malignancy due to immunosuppression remain to be an issue. One of the most common malignancies encountered in the post–solid organ transplant is lymphoproliferative disorder likely developed as a consequence of immunosuppression. We report a case of plasma cell type lymphoma in the ileocecal region of a 45-year-old male kidney transplant patient who was on a tacrolimus-based regimen for ten years. Although literature data indicate differently localized lymphoma as an adverse reaction to the long term use of tacrolimus, to our knowledge, this is the first described case of lymphoma in the ileocecal region. Serious adverse drug reactions and potential toxicity of tacrolimus emphasize the importance of finding the optimal balance between effective drug concentration and the risk associated with its use.

 

Key words

adverse reaction; immunosuppressive therapy; malignancy; tacrolimus; toxicity

 

 

References

 

1. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005; 80: 254-64.
2. Zmonarski SC, Boraynska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M. Kaposi’s sarcoma in renal transplant resipients. Ann Transplant. 2005; 10: 59-65.
3. Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anti-cancer effecrs of immunosupressive agents used in organ transplantation. Transplantation. 2004; 77: 1777-82.
4. Hartevelt MM, Bavinck JN, Koottee AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation. 1990; 49: 506-9.
5. Khedmat H, Taheri S. Late onset post transplantation lymphoproliferative disoreders: analysis of international data from 5 studies. Ann Transplant. 2009;14:80-5.
6. Mihaljevic B, Antic D, Vukovic V, Perunicic Jovanovic M, Lezaic V, Zaric N, · Kerkez M, Djordjevic V. Primary Intestinal Hodgkin Lymphoma Mimicking Intraabdominal Abscess in a Renal Transplant Recipient: A Case Report. Oncol Res Treat. 2016;39:817-21.
7. Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E, et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007; 13: 63-9.
8. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007; 22: 4-10.
9. Özkan EA, Handan Özdemir B, Ebru Deniz E, Zeyneb Tunca M, Haberal M. Posttransplant lymphoproliferative disorder after liver and kidney transplant. Exp Clin Transplant. 2014; 12:142-8.
10. Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011; 16:14-8.
11. Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G, et al. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol. 2014; 53:669-79.
12. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4:87-93.
13. Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosupression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004; 4:87-93.

UDK: 615.015-053.2
613.25-053.2
COBISS.SR-ID 226160396

PDF Đorđević V. et al •MD-Medical Data 2016;8(4): 265-268